NY-PHILIP-MORRIS-INTL
Philip Morris International Inc. (PMI) (NYSE: PM) today announced the launch of IQOS ILUMA i, the latest and most innovative addition to its growing portfolio of smoke-free products for adults who would otherwise continue to smoke or use nicotine products. Today, this range of better alternatives to cigarettes includes multiple generations of IQOS, the No. 1 tobacco heating system.1 The launch also marks the 10-Year anniversary of IQOS, originally launching in Nagoya, Japan in 2014.
“We leverage science, world leading brands and commercial capabilities to provide better alternatives to our consumers. This anniversary provides an opportunity to renew our smoke-free vision and our ambition for over two-thirds of our total net revenue to come from smoke-free products by 2030,” said PMI CEO Jacek Olczak. “IQOS ILUMA disrupted the category by introducing induction-heating technology that heats tobacco from within, to provide a consistent taste experience, no tobacco residue, and no need to clean the device. Today, we take IQOS to new heights, with the launch of IQOS ILUMA i—the latest innovation in our smoke-free portfolio, offering a range of advanced features for a clean, seamless, and more flexible experience.”
Over the past 10 years, PMI’s portfolio of scientifically backed smoke-free alternatives, led by IQOS, has created a positive impact on millions of adult smokers and those around them by accelerating an end to cigarettes. Within 10 years, IQOS net revenues have surpassed those for Marlboro, making it the number one international nicotine brand and accelerated the decline of cigarettes in many countries. In Japan, for example, nearly one-third of adult smokers are using IQOS2 and cigarette sales have declined much more rapidly since heated tobacco was launched. Today, there are 25 markets where PMI’s smoke-free product revenues exceed 50% of total net revenue, including Bulgaria, Czech Republic, Denmark, Greece, Italy, Poland, and Romania.
“IQOS ILUMA i is our most innovative offering to date and the new flagship in our portfolio of scientifically substantiated, heat-not-burn smoke-free systems,” said Bertrand Bonvin, President Heat-Not-Burn Platforms at PMI. “Like previous IQOS devices, it emits, on average, 95% lower levels of harmful chemicals compared with cigarettes.3,4 We are proud that consumer feedback continuously fuels our innovation, and IQOS ILUMA i is a testament to that.”
Olczak added: “We have been investing heavily in research and development to provide adults who smoke with better alternatives to cigarettes based on cutting-edge science. But for change to be effectively enacted, government and society at large must play their part. It is important that others—like government authorities and regulators—embrace the opportunity offered by innovation and science to benefit the world.”
IQOS ILUMA i features
The IQOS ILUMA i series offers three devices in Japan: IQOS ILUMA i PRIME, IQOS ILUMA i and IQOS ILUMA i ONE. All three devices bring a range of adaptable new features. It already delivers an experience that is clean, seamless, and pleasurable thanks to PMI’s bladeless SMARTCORE INDUCTION SYSTEMTM in a variety of designs to meet the diverse preferences of consumers.
The new touch screen on the device’s holder allows users to see experience-relevant information quickly and easily. To personalize the experience, IQOS ILUMA i introduces a new Pause Mode. By swiping up or down on the touch screen, users can pause and resume their smoke-free moment where they left off5, without worrying about wasting a stick. Additionally, FlexPuff allows users to enjoy the experience at their pace6.
The new IQOS ILUMA i additionally includes smart features like FlexBattery that help prolong the lifespan of the holder’s battery7, contributing to electronic waste reduction, as part of our efforts to reduce the environmental impact of our products. Furthermore, the door for IQOS ILUMA i is made from aluminum produced with renewable energy and the inner textile layer of IQOS ILUMA i’s PRIME leather-like wrap is made of 100% recycled plastic.
Further information on IQOS ILUMA i, its features, and additional important information can be found on https://www.IQOS.com.
Philip Morris International: Delivering a Smoke-Free Future
Philip Morris International (PMI) is a leading international tobacco company, actively delivering a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector. The company’s current product portfolio primarily consists of cigarettes and smoke-free products. Since 2008, PMI has invested $12.5 billion to develop, scientifically substantiate and commercialize innovative smoke-free products for adults who would otherwise continue to smoke, with the goal of completely ending the sale of cigarettes. This includes the building of world-class scientific assessment capabilities, notably in the areas of pre-clinical systems toxicology, clinical and behavioural research, as well as post-market studies. In 2022, PMI acquired Swedish Match – a leader in oral nicotine delivery – creating a global smoke-free champion led by the companies’ IQOS and ZYN brands. The U.S. Food and Drug Administration has authorized versions of PMI’s IQOS Platform 1 devices and consumables and Swedish Match’s General snus as Modified Risk Tobacco Products. As of December 31, 2023, PMI's smoke-free products were available for sale in 84 markets, and PMI estimates that approximately 20.8 million adults around the world had already switched to IQOS and stopped smoking. Smoke-free products accounted for approximately 37% of PMI’s total full-year 2023 net revenues. With a strong foundation and significant expertise in life sciences, PMI announced in February 2021 its ambition to expand into wellness and healthcare areas and, through its Vectura Fertin Pharma business, aims to enhance life through the delivery of seamless health experiences. For more information, please visit www.pmi.com and www.pmiscience.com.
1 Source: PMI global estimate of total In-Market Sales of Heated Tobacco Units as of June 2023.
2 HTU city offtake share [Q3, 2023] of total cigarettes and HTUs. Source: PMI Financials or estimates.
3 Important information: It does not necessarily equal a 95% reduction in risk. IQOS is not risk-free and provides nicotine, which is addictive. Only for use by adults.
4 ”95% less” represents the average reductions in levels of a range of harmful chemicals (excluding nicotine) compared to the smoke of a reference cigarette (3R4F). See Important Information on www. iqos.com.
5 Only available in Performance Mode, during the first 3 minutes or 8 puffs of the experience. When pause is activated, Performance Mode gives you up to two consecutive experiences and pause is available only for one of them.
6 FlexPuff activation and number of puffs depend on individual usage patterns, thus extra puffs might not apply to all adult consumers and/or experiences. FlexPuff does not activate when pause is used.
7 Only when fully used on Eco Mode throughout the lifespan of the holder and may vary depending on personal consumption.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240313137812/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sai Life Sciences Opens Dedicated Facility for Veterinary APIs in Bidar, India18.9.2025 18:22:00 CEST | Press release
Sai Life Sciences (BSE: 544306 | NSE: SAILIFE), an innovator-focused Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the opening of Unit VI, a dedicated facility for Veterinary Active Pharmaceutical Ingredient (API) production, in Bidar, India. Located alongside Unit IV, the company’s flagship API manufacturing site, Unit VI has been established exclusively for veterinary APIs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918612071/en/ Sai Life Sciences’ Veterinary APIs Unit in Bidar, India. The new facility is designed to meet the highest standards of safety, sustainability, and regulatory compliance, ensuring the production of high-quality APIs for veterinary applications. With this expansion, Sai Life Sciences aims to provide efficient and scalable manufacturing solutions to leading global animal health companies. Making the announcement, Krishna Kanumuri, CEO & Managing Direct
Celltrion Announces Commercial Availability of Omlyclo™ Across Europe at EADV 202518.9.2025 17:45:00 CEST | Press release
Celltrion’s Omlyclo™, the first and only omalizumab biosimilar in Europe, will be commercially available starting in Norway, with subsequent rollouts in European countries Results from the global Phase III clinical trial of Omlyclo™ (CT-P39) for the treatment of chronic spontaneous urticaria (CSU), allergic asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) will be presented at a satellite symposium during the 2025 European Academy of Dermatology and Venereology (EADV) Congress Celltrion highlights the strength of its expanding dermatology portfolio with positive clinical results for CT-P55, a biosimilar candidate referencing secukinumab With the launch of Omlyclo™, Celltrion underscores its commitment to advancing innovative and accessible treatments in immunology and dermatology Celltrion, Inc. today showcased its longstanding commitment to expanding its biosimilar portfolio in the field of immuno-dermatology by attending the 2025 European Academy of Dermatology and Venereo
Andersen Consulting tilføjer samarbejdsfirmaet Charter18.9.2025 17:14:00 CEST | Pressemeddelelse
Andersen Consulting udvider sine digitale transformationskapaciteter gennem en samarbejdsaftale med Charter, et canadisk konsulentfirma, der er specialiseret i IT-strategi, managed services og applikationslevering. Charter blev grundlagt i 1997 og leverer teknologiprojekter med en forretningsorienteret tankegang og dyb teknisk ekspertise, herunder inden for IT-rådgivning, cloud-infrastruktur, cybersikkerhed, applikationsudvikling, projektlevering og forretningsarkitektur. Charter hjælper traditionelle virksomheder, offentlige institutioner, tjenesteudbydere og mellemstore kunder med implementering, netværksinfrastruktur og kundeorienterede applikationer – der leveres gennem en livscyklus-tilgang fra strategi til udførelse. "Vores mål hos Charter har altid været at fjerne kompleksiteten fra IT og hjælpe organisationer med at bevæge sig fremad med tillid," siger Kelly Michell, præsident for Charter. "Vores samarbejde med Andersen Consulting gør det muligt for os at bringe vores integrere
Andersen Consulting udvider sit udbud inden for cybersikkerhed og teknologi med tilføjelsen af Move18.9.2025 17:06:00 CEST | Pressemeddelelse
Andersen Consulting har indgået en samarbejdsaftale med Move, der er en førende virksomhed inden for it-infrastruktur, driftstjenester og digitale løsninger til virksomheder. Move befinder sig i Norge og Sverige. Move blev grundlagt i 1989 og leverer konsulentydelser, it-løsninger og driftstjenester. Virksomheden har ekspertise inden for cybersikkerhed, cloud-løsninger, server- og lagringsløsninger, netværkskommunikation og implementering af AI. Move samarbejder med mellemstore og store virksomheder om at designe, implementere og drive sikre, skalerbare og fremtidssikrede it-miljøer. "Dette samarbejde er en spændende mulighed for at skabe endnu større værdi for vores kunder," siger Roald Sannæs, der er administrerende direktør i Move. "Med vores kompetencer og Andersen Consultings globale rækkevidde og ekspertise kan vi levere mere helhedsorienterede løsninger, der hjælper organisationer med at løse nutidens udfordringer og forudse fremtidens muligheder." "Move har opbygget et godt ren
Setting the Standard: AMRA Medical Recognized as one of TIME Magazine’s ‘World’s Top HealthTech Companies’18.9.2025 16:40:00 CEST | Press release
The inaugural ranking by TIME, in partnership with Statista, features AMRA as one of the world’s leading health technology companies that are “driving innovation, enhancing accessibility, and contributing to a more effective and sustainable health care system” AMRA Medical is proud to share its inclusion in the World’s Top HealthTech Companies list, published today by TIME in collaboration with Statista. This recognition positions AMRA among an elite group of global innovators that are leading healthcare transformation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918372780/en/ AMRA Medical Recognized as one of TIME Magazine’s ‘World’s Top HealthTech Companies’ The selection, which comes just one week after celebrating AMRA’s 15 years of progress and innovation within the body composition space, highlights AMRA’s long-standing commitment to becoming a global leader in health informatics. By delivering detailed, reproduc
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom